Here's the reader question that trips up almost everyone scanning biotech news: a company "has a patent" on something — but does it? Often the headline is describing a patent application, not a granted patent, and the difference is the difference between owning a right and asking for one.

Start with the granted patent. When a patent office examines an application and decides the claims are new and valid, it issues the patent. From that point the owner has an enforceable right: they can sue a competitor for infringement. You can spot grants in the record by their issue date and kind code — a US grant typically carries a "B2" suffix. For example, Eli Lilly's US12616740B2 is a granted patent, issued May 5, 2026. That "B2" and the issue date tell you it's enforceable.

“The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof.”— U.S. Patent No. 12,616,740 source

Now the published application. While an application is still under review, it's usually published for the public to see — but publication is not approval. It carries a code like "A1" and a publication date, not an issue date, and crucially it confers no enforceable rights yet. The tri-agonist filing US20260151493A1 is a published application: a request describing claims the office has not yet allowed. The company is staking a position, not holding a weapon.

Why does this decide real money in biotech? Because a granted patent can block a competitor's product launch, while a pending application generally cannot. Treating an A1 publication as if it were a B2 grant can lead a reader to overestimate how protected a drug is — or how blocked a rival is. The codes are small, but they carry the entire legal weight.

There's a second, subtler reason to read the type carefully. Applications reveal intent and direction — they show what a company is trying to claim, which is genuinely useful for understanding strategy. But the claims in a published application frequently get narrowed before they're granted, or rejected entirely. So an application tells you where someone is aiming; only a grant tells you what they actually hit.

The rule of thumb, then, lead with the type. Before you conclude anything from "Company X patented Y," check whether the record is a grant (issued, B2, enforceable) or an application (published, A1, pending). On this site, every patent we cite is labeled and deep-linked so you can verify it yourself — because in biotech, the gap between a grant and an application is the gap between protection and hope.